14 active not recruiting. 14 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Active not recruiting 14 |
| Phase 2 | 4 | Active not recruiting 4 |
Follow Inflammation: new trials by email Literature Review of Inflammation trials Research Report on Inflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation Ketofol, propofol (drug) - The Critically Ill Patient is Requiring Intubation, Septic Shock | Phase 3 | Active not recruiting | Helwan University | 70 | 2026-05-13 | 2026-10-15 |
| A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women GBS-NN/NN2 vaccine - Streptococcus Agalactiae Infection, Neonatal Sepsis | Phase 2 / Phase 3 | Active not recruiting | Minervax ApS | 137 | 2025-03-07 | 2026-09-04 |
| An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) Sonelokimab - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | MoonLake Immunotherapeutics AG | 35 | 2024-12-30 | 2026-05-06 |
| A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) Andecaliximab, Placebo - Fibrodysplasia Ossificans Progressiva | Phase 2 / Phase 3 | Active not recruiting | Ashibio Inc | 92 | 2024-10-25 | 2025-10-14 |
| Specifying the Anti-inflammatory Effects of Ziltivekimab Ziltivekimab, Placebo - Atherosclerosis, Inflammation | Phase 3 | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 40 | 2024-05-03 | 2026-08-06 |
| Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement Chlorhexidine, Gentamicin, Rifampin - Erectile Dysfunction, Penile Prosthesis; Complications, Infection or Inflammation | Phase 3 | Active not recruiting | Rush University Medical Center | 200 | 2023-12-04 | 2026-07-24 |
| Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial) Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results., Standard of Care - Sepsis | Phase 3 | Active not recruiting | Hellenic Institute for the Study of Sepsis | 190 | 2023-09-19 | 2026-01-16 |
| Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women MWSH plus Candlelit Care, MWSH - Pregnancy Related, Pregnancy Complications | Phase 2 / Phase 3 | Active not recruiting | Cedars-Sinai Medical Center | 150 | 2023-06-01 | 2026-10-22 |
| Colchicine and Inflammation in Aortic Stenosis Colchicine, Placebo - Aortic Valve Disease, Aortic Valve Stenosis | Phase 3 | Active not recruiting | Radboud University Medical Center | 150 | 2022-12-22 | 2026-08-27 |
| Preventing Cognitive Decline with Metformin Metformin XR, 500-2000mg nocte - Cognitive Decline | Phase 3 | Active not recruiting | Garvan Institute of Medical Research | 242 | 2022-07-15 | 2024-10-02 |
| Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis Vasopressor, Fluids - Shock, Septic | Phase 3 | Active not recruiting | Australian and New Zealand Intensive Care Research Centre | 1000 | 2021-10-26 | 2026-03-17 |
| Local Antibiotics for Breast Implants Gentamicin, Cefazolin and Vancomycin, Placebo - Implant Complication, Implant Infection | Phase 3 | Active not recruiting | Mikkel Herly | 1003 | 2021-01-27 | 2026-09-29 |
| Does High-dose Vitamin B3 Supplementation Prevent Major Adverse Kidney Events During Septic Shock? Nicotinamide treatment, placebo treatment - Acute Kidney Injury, Septic Shock | Phase 3 | Active not recruiting | Centre Hospitalier Universitaire, Amiens | 310 | 2020-10-01 | 2025-08-24 |
| Human Milk Fortification in Extremely Preterm Infants H2MF, Bovine milk-based fortifier - Necrotizing Enterocolitis, Sepsis | Phase 2 / Phase 3 | Active not recruiting | Thomas Abrahamsson, MD, PhD | 229 | 2019-02-01 | 2024-07-23 |
Infections (3) · Shock, Septic (3) · Pneumonia (2) · Sepsis (2) · Acute Kidney Injury (1) · Anxiety Disorders (1) · Aortic Valve Disease (1) · Aortic Valve Stenosis (1) · Aortic Valve, Calcification of (1) · Atherosclerosis (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Calcinosis (1) · Cardiovascular Diseases (1)
Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Systemic Inflammatory Response Syndrome (6) · Infections (5) · Sepsis (4) · Mental Disorders (3) · Nervous System Diseases (3) · Shock (3) · Urogenital Diseases (3) · Cardiovascular Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Lung Diseases (2) · Male Urogenital Diseases (2) · Metabolic Diseases (2)
Gentamicins (2) · Cefazolin (1) · Chlorhexidine (1) · Colchicine (1) · Fluid Therapy (1) · Pharmaceutical Preparations (1) · Propofol (1) · Rifampin (1) · Standard of Care (1) · Vancomycin (1) · Vasoconstrictor Agents (1) · andecaliximab (1) · sonelokimab (1) · ziltivekimab (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Ashibio Inc (1) · Australian and New Zealand Intensive Care Research Centre (1) · Cedars-Sinai Medical Center (1) · Centre Hospitalier Universitaire, Amiens (1) · Garvan Institute of Medical Research (1) · Hellenic Institute for the Study of Sepsis (1) · Helwan University (1) · Mikkel Herly (1) · Minervax ApS (1) · MoonLake Immunotherapeutics AG (1) · Radboud University Medical Center (1) · Rush University Medical Center (1) · Thomas Abrahamsson, MD, PhD (1)
United States (4) · Australia (2) · Denmark (2) · Netherlands (2) · Egypt (1) · France (1) · Greece (1) · Ireland (1) · New Zealand (1) · South Africa (1) · Sweden (1)
Edward Cherullo, MD (1) · Evangelos Giamarellos-Bourboulis, MD,PhD (1) · Laurence Levine, MD (1) · Mikkel Herly, MD, Ph.D. (1) · Sandra Peake, MBBS (1) · Thomas R Abrahamsson, MD, PhD (1)
PMID 34815288, PMID 36115667, PMID 38545091, PMID 39434728, PMID 40659197, PMID 40685240, PMID 42274006
R21MD017396 (1)